Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Pratiti Bandopadhayay, Ph.D., M.B.,B.S.

Co-Author

This page shows the publications co-authored by Pratiti Bandopadhayay and Rameen Beroukhim.
Connection Strength

3.388
  1. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400.
    View in: PubMed
    Score: 0.840
  2. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat Commun. 2019 08 19; 10(1):3731.
    View in: PubMed
    Score: 0.213
  3. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 2018 04; 28(4):581-591.
    View in: PubMed
    Score: 0.193
  4. Open data: Spot data glitches before publication. Nature. 2017 10 18; 550(7676):333.
    View in: PubMed
    Score: 0.188
  5. Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife. 2017 02 08; 6.
    View in: PubMed
    Score: 0.179
  6. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol. 2016 06; 128(2):293-302.
    View in: PubMed
    Score: 0.168
  7. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016 Mar; 48(3):273-82.
    View in: PubMed
    Score: 0.167
  8. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016 Jan; 126(1):165-174.
    View in: PubMed
    Score: 0.166
  9. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96.
    View in: PubMed
    Score: 0.157
  10. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9.
    View in: PubMed
    Score: 0.145
  11. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014 Feb 15; 20(4):912-25.
    View in: PubMed
    Score: 0.143
  12. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell. 2020 12 10; 183(6):1617-1633.e22.
    View in: PubMed
    Score: 0.058
  13. CloneSifter: enrichment of rare clones from heterogeneous cell populations. BMC Biol. 2020 11 24; 18(1):177.
    View in: PubMed
    Score: 0.058
  14. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
    View in: PubMed
    Score: 0.056
  15. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020 02; 578(7793):102-111.
    View in: PubMed
    Score: 0.055
  16. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020 01 13; 37(1):104-122.e12.
    View in: PubMed
    Score: 0.055
  17. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019 12; 576(7785):112-120.
    View in: PubMed
    Score: 0.054
  18. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 08 05; 21(8):968-980.
    View in: PubMed
    Score: 0.053
  19. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8.
    View in: PubMed
    Score: 0.052
  20. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell. 2018 12 10; 34(6):922-938.e7.
    View in: PubMed
    Score: 0.051
  21. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018 08; 560(7718):325-330.
    View in: PubMed
    Score: 0.050
  22. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335.
    View in: PubMed
    Score: 0.049
  23. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996.
    View in: PubMed
    Score: 0.046
  24. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30.
    View in: PubMed
    Score: 0.043
  25. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015 Jan 06; 112(1):232-7.
    View in: PubMed
    Score: 0.039
  26. Epigenetic targeting of hedgehog pathway transcriptional output. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii25.
    View in: PubMed
    Score: 0.037
  27. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014 Jul; 20(7):732-40.
    View in: PubMed
    Score: 0.037
  28. Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta. 2014 Apr; 1845(2):294-307.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.